Abstract
This investigation was designed to determine the effect of experimental hyperthyroidism on the hypnotic activity of a benzodiazepine and on the binding characteristics of the benzodiazepine receptor complex. Rats were made hyperthyroid by subcutaneous implantation of slow release pellets containing L-thyroxine. This treatment produced the characteristic symptoms of hyperthyroidism: increased serum thyroxine concentrations, increased heart weight and body temperature, and decreased serum protein concentrations. The hyperthyroid rats and a parallel group of normal animals (with drug-free pellets implanted subcutaneously) were slowly infused intravenously with oxazepam until they lost their righting reflex. The hyperthyroid rats required a significantly larger dose of the benzodiazepine and their total serum and cerebrospinal fluid concentrations of oxazepam (but not the serum concentration of free drug and the brain concentration) at the onset of loss of the righting reflex were modestly but statistically significantly lower than those of the normal rats. The receptor density and affinity for diazepam in hyperthyroid rats were not significantly different from those of the normal animals. Hyperthyroidism apparently affects the pharmacokinetics of oxazepam but has, at best, only a small effect on the pharmacodynamics (hypnotic activity) of the drug.
Similar content being viewed by others
REFERENCES
A. Nagy and A. Lajtha. J. Neurochem. 40:414–417 (1983).
J. H. Medina and E. De Robertis. J. Neurochem. 44:1340–1344 (1985).
C. K. Atterwill and D. J. Nutt. J. Pharm. Pharmacol. 35:767–768 (1983).
P. M. Klockowski and G. Levy. J. Pharmacol. Exp. Ther. 244:912–918 (1988).
P. M. Klockowski and G. Levy. J. Chromatogr. 422:334–339 (1987).
P. M. Klockowski and G. Levy. J. Pharmacol. Exp. Ther. 245:508–512 (1988).
J. H. Zar. Biostatistical Analysis, 2nd ed., Prentice-Hall, Englewood Cliffs, N.J., 1984, pp. 40–41.
P. O'Connor and J. Feely. Clin. Pharmacokin. 13:345–364 (1987).
A. K. Scott, A. S. M. Khir, P. D. Bewsher, and G. M. Hawksworth. Br. J. Clin. Pharmacol. 17:49–53 (1984).
A. J. Prange, Jr., M. A. Lipton, R. B. Shearin, and G. N. Love. Biochem. Pharmacol. 15:237–248 (1966).
R. D. Harbison and B. A. Becker. J. Pharm. Sci. 58:183–185 (1969).
J. Dingemanse, F. A. E. Sollie, D. D. Breimer, and M. Danhof. J. Pharmacokin. Biopharm. 16:203–228 (1988).
H. Mohler and T. Okada. Science 198:849–851 (1977).
P. A. Borea and A. Bonora. Biochem. Pharmacol. 32:603–607 (1983).
W. Sieghart and A. Schuster. Biochem. Pharmacol. 33:4033–4038 (1984).
E. DeRobertis, C. Pena, A. C. Paladini, and J. H. Medina. Neurochem. Int. 13:1–11 (1988).
K. D. Mullen, J. V. Martin, W. B. Mendelson, M. L. Bassett, and E. A. Jones. Lancet 1:457–459 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Walker, J.S., Klockowski, P.M. & Levy, G. Kinetics of Drug Action in Disease States. XXXI. Effect of Experimental Hyperthyroidism on the Hypnotic Activity of a Benzodiazepine (Oxazepam) in Rats. Pharm Res 6, 404–407 (1989). https://doi.org/10.1023/A:1015983415887
Issue Date:
DOI: https://doi.org/10.1023/A:1015983415887